{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:17:36Z","timestamp":1785849456372,"version":"3.56.0"},"reference-count":39,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institute for Maternal and Child Health - IRCCS \u201cBurlo Garofolo\u201d, Trieste (Italy)","award":["RC #24\/2017"],"award-info":[{"award-number":["RC #24\/2017"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Off-label use of medications is still a common practice in pediatric rheumatology. JAK inhibitors are authorized in adults in the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Although their use is not authorized yet in children, JAK inhibitors, based on their mechanism of action and on clinical experiences in small series, have been suggested to be useful in the treatment of pediatric interferon-mediated inflammation. Accordingly, an increased interferon score may help to identify those patients who might benefit of JAK inhibitors. We describe the clinical experience with JAK inhibitors in seven children affected with severe inflammatory conditions and we discuss the correlation between clinical features and transcriptomic data. Clinical improvements were recorded in all cases. A reduction of interferon signaling was recorded in three out of seven subjects at last follow-up, irrespectively from clinical improvements. Other signal pathways with significant differences between patients and controls included upregulation of DNA repair pathway and downregulation of extracellular collagen homeostasis. Two patients developed drug-related adverse events, which were considered serious in one case. In conclusion, JAK inhibitors may offer a valuable option for children with severe interferon-mediated inflammatory disorders reducing the interferon score as well as influencing other signal pathways that deserve future studies.<\/jats:p>","DOI":"10.3390\/ijms21207767","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T09:28:23Z","timestamp":1603186103000},"page":"7767","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-1976","authenticated-orcid":false,"given":"Alessia","family":"Pin","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health\u2014IRCCS \u201cBurlo Garofolo\u201d, 34137 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6267-3794","authenticated-orcid":false,"given":"Alessandra","family":"Tesser","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health\u2014IRCCS \u201cBurlo Garofolo\u201d, 34137 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pastore","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health\u2014IRCCS \u201cBurlo Garofolo\u201d, 34137 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-5431","authenticated-orcid":false,"given":"Valentina","family":"Moressa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health\u2014IRCCS \u201cBurlo Garofolo\u201d, 34137 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Valencic","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health\u2014IRCCS \u201cBurlo Garofolo\u201d, 34137 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Arbo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Clinical Pharmacology, Institute for Maternal and Child Health\u2014IRCCS \u201cBurlo Garofolo\u201d, 34137 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Maestro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Clinical Pharmacology, Institute for Maternal and Child Health\u2014IRCCS \u201cBurlo Garofolo\u201d, 34137 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-7927","authenticated-orcid":false,"given":"Alberto","family":"Tommasini","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health\u2014IRCCS \u201cBurlo Garofolo\u201d, 34137 Trieste, Italy"},{"name":"Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Taddio","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute for Maternal and Child Health\u2014IRCCS \u201cBurlo Garofolo\u201d, 34137 Trieste, Italy"},{"name":"Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41584-019-0361-0","article-title":"Machine learning in rheumatology approaches the clinic","volume":"16","author":"Pandit","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1056\/NEJMc2001362","article-title":"Janus Kinase Inhibition in the Aicardi-Gouti\u00e8res Syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"273907","article-title":"Activation of type I interferon pathway in systemic lupus erythematosus: Association with distinct clinical phenotypes","volume":"2011","author":"Karageorgas","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1002\/art.34652","article-title":"A preliminary disease severity score for juvenile systemic sclerosis","volume":"64","author":"Martini","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/jir.2017.0127","article-title":"Development of a Validated Interferon Score Using NanoString Technology","volume":"38","author":"Kim","year":"2018","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_6","first-page":"374312","article-title":"Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-\u03b1 Monoclonal Antibody Trials in Systemic Lupus Erythematosus","volume":"2009","author":"Yao","year":"2009","journal-title":"Hum. Genom. Proteom."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"D362","DOI":"10.1093\/nar\/gkw937","article-title":"The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible","volume":"45","author":"Szklarczyk","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gkn923","article-title":"Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists","volume":"37","author":"Huang","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Trombetta, A., Ghirardo, S., Pastore, S., Tesser, A., Piscianz, E., Tommasini, A., Bobbo, M., and Taddio, A. (2019). Pulmonary arterial hypertension in interferonophaties: A case report and a review of the literature. Pulm. Circ., 9.","DOI":"10.1177\/2045894019869837"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40272-017-0261-1","article-title":"Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation","volume":"19","author":"Tomasi","year":"2017","journal-title":"Paediatr. Drugs"},{"key":"ref_12","first-page":"316","article-title":"Unlicensed and Off-Label Drug Use in Children Before and After Pediatric Governmental Initiatives","volume":"20","author":"Corny","year":"2015","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-016-0507-y","article-title":"Off-label use of orphan medicinal products: A Belgian qualitative study","volume":"11","author":"Dooms","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.2174\/0929867324666170830101215","article-title":"Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine","volume":"25","author":"Valencic","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41586-019-1879-7","article-title":"A brief history of human disease genetics","volume":"577","author":"Claussnitzer","year":"2020","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3389\/fimmu.2019.02813","article-title":"Current State of Precision Medicine in Primary Systemic Vasculitides","volume":"10","author":"Demirkaya","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/BOR.0000000000000419","article-title":"Precision medicine in pediatric rheumatology","volume":"29","author":"Yeo","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1517\/14740338.2014.928692","article-title":"The importance of monitoring adverse drug reactions in pediatric patients: The results of a national surveillance program in Italy","volume":"13","author":"Carnovale","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10875-019-00645-0","article-title":"Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome","volume":"39","author":"Volpi","year":"2019","journal-title":"J. Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/ard.2008.093146","article-title":"Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus","volume":"68","author":"Bonventi","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kawanishi, S., Ohnishi, S., Ma, N., Hiraku, Y., and Murata, M. (2017). Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Carcinogenesis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081808"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Souliotis, V.L., Vlachogiannis, N.I., Pappa, M., Argyriou, A., Ntouros, P.A., and Sfikakis, P.P. (2019). DNA Damage Response and Oxidative Stress in Systemic Autoimmunity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010055"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1002\/jcp.27507","article-title":"Proinflammatory macrophages promote degenerative phenotypes in rat nucleus pulpous cells partly through ERK and JNK signaling","volume":"234","author":"Ni","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13075-019-1929-4","article-title":"Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles","volume":"21","author":"Reynolds","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/eji.201847683","article-title":"Dendritic cells modulate c-kit expression on the edge between activation and death","volume":"49","author":"Simonetti","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.molmet.2016.05.006","article-title":"Lack of AKT in adipocytes causes severe lipodystrophy","volume":"5","author":"Shearin","year":"2016","journal-title":"Mol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: An efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"},{"key":"ref_37","first-page":"100","article-title":"A k-means clustering algorithm","volume":"28","author":"Hartigan","year":"1979","journal-title":"J. R. Stat. Soc. Ser. C (Appl. Stat.)"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3389\/fgene.2019.00858","article-title":"pathfindR: An R Package for Comprehensive Identification of Enriched Pathways in Omics Data Through Active Subnetworks","volume":"10","author":"Ulgen","year":"2019","journal-title":"Front. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/20\/7767\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:24:49Z","timestamp":1760178289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/20\/7767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":39,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21207767"],"URL":"https:\/\/doi.org\/10.3390\/ijms21207767","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]}}}